US2017119746A1PendingUtilityA1

Preparation and therapeutic applications of (2s,3r)-n-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide

47
Assignee: ATTENUA INCPriority: Jan 26, 2009Filed: Sep 28, 2015Published: May 4, 2017
Est. expiryJan 26, 2029(~2.5 yrs left)· nominal 20-yr term from priority
A61P 35/00A61P 9/00A61P 9/10A61P 43/00A61P 3/10A61P 37/06A61P 7/02A61P 3/00A61P 25/06A61P 25/28A61P 25/04A61P 25/00A61P 29/00A61P 3/04A61P 25/02A61P 25/18A61P 19/06A61P 1/02A61P 17/04A61P 11/00A61P 17/06A61P 1/16A61P 1/04A61P 13/12A61P 19/02A61P 17/00A61P 11/06A61K 31/444C07D 471/08C07D 453/04A61K 31/439C07D 453/02
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

Claims

exact text as granted — not AI-modified
That which is claimed is: 
     
         1 . A method for treating a neurodegenerative disorder, comprising administering to a patient in need thereof an effective amount of a compound (2S,3R)—N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide (Formula I) or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.